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Background: The presence of multiple metastatic pulmonary nodules is a predictor of poor survival after
pulmonary metastasectomy. However, there is a paucity of data addressing the exact number of pulmonary
metastases over which prognosis becomes grave. The aim of our study is to investigate the prognosis of
pulmonary metastasectomy from colorectal cancer (CRC) depending on the number of pulmonary metastases.
Methods: Patients who had undergone pulmonary metastasectomy for CRC between November 1994 and
December 2013 were included. Survival and recurrence patterns were analyzed with regard to the number of
pulmonary metastases. Patients were divided into three groups depending on the number of pulmonary
metastases that were detected by the final pathologic report: group I—single metastasis; group II—2–3 metastases;
and group III—4+ metastases.
Results: A total of 615 patients who had undergone pulmonary metastasectomy from colorectal cancer were
included. The median follow-up period was 31 months (range 2–211 months). The median disease-free interval (DFI)
from the time of the primary operation for colorectal cancer was 20 months (range 0–209 months). There were 414
patients in group I (single metastasis), 159 in group II (2–3 metastases), and 42 in group III (4+ metastases). The overall
5-year survival rate was 64.2 %. The 5-year survival rates in groups I, II, and III were 70.0, 56.2, and 33.7 %, respectively
(group I vs. II, p < 0.001; group II vs. III, p = 0.012). The 5-year recurrence-free rates were 39.5, 30.6, and 8.5 % in groups I,
II, and III, respectively (group I vs. II, p < 0.001; group II vs. III, p = 0.056). Multivariable analysis revealed that age, multiple
pulmonary nodules, thoracic lymph node metastasis, and adjuvant chemotherapy are independent predictors of
survival.
Conclusions: The overall survival and recurrence after pulmonary metastasectomy for CRC is dependent on the
number of metastases. Surgical treatment can be offered to patients with three or fewer pulmonary metastases.
However, more meticulous patient selection is required to decide whether a surgical approach is feasible in patients
with four or more pulmonary metastases.
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Approximately half of the patients who undergo resec-
tion of colorectal cancer (CRC) will develop metastatic
disease and 5–15 % of those eventually develop lung
metastases [1, 2]. Pulmonary metastases from CRC re-
sult from systemic tumor spread. Fortunately, the surgi-
cal resection of lung metastases can be curative in
select patients. In the presence of pulmonary metasta-
ses, the treatment of choice depends on an assessment
of resectability. There are several proposed prognostic
factors that are related to survival and tumor recur-
rence after CRC pulmonary metastasectomy. The num-
ber of pulmonary metastases is negatively correlated to
survival after pulmonary metastasectomy. Several stud-
ies have reported that patients with solitary lesions con-
sistently have higher survival rates than do those with
multiple lesions [3–5]. However, there is no known cut-
off number of pulmonary metastases that influences
metastasectomy success.
Our strategy in metastatic CRC has been to offer sur-
gery as long as resectability and operability can be guar-
anteed, regardless of the number of pulmonary
metastases. We reviewed prior cases to investigate the
prognosis of pulmonary metastasectomy depending on
the number of pulmonary metastases.
Methods
Patients and data collection
Data were collected on patients who underwent lung
metastasectomy (from CRC) between November 1994
and December 2013. The patients’ baseline characteris-
tics and treatment modalities were obtained from the
medical records. Patients were included if they had the
following: (1) complete resection for cure or control of
primary CRC, (2) no extrapulmonary metastasis that
precluded resection, and (3) a follow-up chest CT or
PET-CT scan at our institution at least twice after sur-
gery. Patients were excluded if there was no available
radiologic information for surveillance after pulmonary
metastasectomy.
Based on the analyses of pulmonary metastasectomy by
the International Registry of Lung Metastases, we divided
patients into three groups according to the number of pul-
monary metastases: group I—single metastasis; group
II—2–3 metastases; and group III—4+ metastases [6]. The
“number of pulmonary metastases” was defined by the
number of pulmonary nodules that were confirmed by the
final pathologic report. Therefore, this number was not
defined by the number of nodules actually resected or by
the number of nodules that were presumed to be metasta-
ses by radiographic studies.
The following parameters were recorded and in-
cluded in the statistical analysis: sex, age, number of
resected pulmonary metastases, disease-free interval(DFI) between primary cancer resection and identifica-
tion of pulmonary metastases, bilaterality, primary
tumor site, surgical approach (thoracotomy, sternot-
omy, video-assisted thoracic surgery (VATS)), type of
surgical resection (precision excision, wedge resection,
segmentectomy, lobectomy, bilobectomy, or pneumon-
ectomy), thoracic lymph node involvement, and admin-
istration of adjuvant chemotherapy.
The location of primary colorectal cancer was defined
as two groups (the colon cancer group and the rectal
cancer group) based on the anatomy of venous drainage.
Patients were defined to have colon cancer if the pri-
mary lesion was between the cecum and rectosigmoid
junction. In contrast, if the primary lesion fell between
the rectosigmoid junction and the anus, patients were
defined as having rectal cancer. Cancers with a distal
margin at the anal verge or within 15 cm of it were clas-
sified as rectal cancer (when the exact anatomical loca-
tion was not specified on the surgical report).
Our study was approved by the Institutional Review
Board of Samsung Medical Center (IRB Number: 2015-
01-089).
Statistical analysis
For comparisons of continuous and categorical vari-
ables, either the Mann–Whitney U test, the χ2 test, or
the Fisher exact test was used as appropriate. The
Kaplan–Meier method was used to plot patient survival
and recurrence curves. The following factors were eval-
uated for their influence on patient survival after pul-
monary metastasectomy: age, gender, maximal tumor
size (largest diameter in centimeters and/or the size of
the largest metastasis), bilaterality, thoracic lymph node
involvement, number of pulmonary metastases, and
preoperative/adjuvant chemotherapy. Kaplan–Meier es-
timates and the log-rank test were used to calculate
survival from the time of the first pulmonary metasta-
sectomy to the last follow-up. A Cox proportional haz-
ards model was used in univariate and multivariate
analysis for these factors. p values <0.05 were consid-
ered statistically significant. All statistical analyses were




A total of 696 patients underwent pulmonary metasta-
sectomy with curative intent for CRC between Novem-
ber 1994 and December 2013. Among them, 81 patients
had incomplete follow-up radiologic information and
were therefore excluded. The remaining 615 patients
were included in our study.
Patient characteristics according to the number of
pulmonary metastases are summarized in Table 1. The
Table 1 Patient characteristics by the number of pulmonary metastases
Characteristics The number of pulmonary metastases p valuea
All patients Group I Group II Group III
N = 615 N = 414 N = 159 N = 42
Age, mean ± sd (years) 58.7 ± 10.4 59.3 ± 10.6 57.5 ± 10.2 57.5 ± 9.2 0.109
Male, n (%) 361 (58.7) 256 (61.8) 82 (51.6) 23 (54.7) 0.073
DFI, median (range), months 20 (0–209) 22 (0–209) 19 (0–112) 15 (0–108) 0.084
Primary CRC location 0.757
Colon cancer, n (%) 244 (39.7) 189 (45.6) 77 (48.4) 18 (42.9)
Rectal cancer, n (%) 371 (60.3) 225 (54.4) 82 (51.6) 24 (57.1)
Preop chemotherapy,
n (%)
370 (54.9) 241 (58.2) 103 (64.8) 26 (61.9) 0.343
Adjuvant chemotherapy,
n (%)
461 (75.0) 296 (71.5) 130 (81.7) 35 (83.3) 0.014
DFI disease-free interval (time between CRC surgery and pulmonary metastasectomy)
aCorrelation between factors was assessed using χ2 test and Student’s t test for continuous variables
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sectomy was 60 (range 26–82 years), and 361 patients
(58.7 %) were male. The median follow-up period was
31.0 months (range 2–211 months). The median disease-
free interval between the CRC surgery and pulmonary
metastasectomy was 20 months (range 0–209). There were
244 primary cancers (39.7 %) in the colon and 371 in the
rectum (60.3 %). Of all 615 patients, 370 (54.7 %) had re-
ceived chemotherapy before pulmonary metastasectomy,
and 461 (75.0 %) received adjuvant chemotherapy. Patients
in groups II and III received more adjuvant chemotherapy
than did those in group I (Table 1).
The number of lung metastases
The mean number of lungs resected was 1.92 ± 1.77.
The mean number of lung metastases was 1.66 ± 1.44.
In 506 patients (82.3 %), every suspicious lung nodule
that was resected was confirmed by pathology to be
metastatic disease. However, in 109 patients (17.7 %),
non-metastatic lesions (previously thought to be metas-
tases) were resected (Fig. 1). Group I (n = 414) con-
sisted of patients with a single pulmonary metastasis.
Group II (n = 159) was made up of patients with two or
three pulmonary metastases, and group III (n = 42) in-
cluded patients with four or more pulmonary metasta-
ses. The mean number of metastases in groups I, II,
and III were 1, 2.28 ± 0.45, and 5.79 ± 2.62, respectively
(group I vs. II—p < 0.001; group II vs. III—p < 0.001).
Surgical approach
The approach and extent of pulmonary metastasectomy
is summarized in Table 2. The median size of the largest
nodule was 1.3 cm (range 0.2–9 cm). There was no sig-
nificant difference in tumor size between the three groups
(p = 0.253). The majority of surgeries were performedusing wedge resection (n = 439, 71.4 %), followed by lobec-
tomy (n = 109, 17.7 %), segmentectomy (n = 41, 6.7 %),
precision excision (n = 20, 3.3 %), bilobectomy (n = 5,
0.8 %), and pneumonectomy (n = 1, 0.2 %). With regard to
surgical approach, 371 patients (60.3 %) underwent VATS,
while the remaining 244 patients (39.7 %) had thoracot-
omy or sternotomy. Thoracotomy and sternotomy were
performed more frequently in groups II and III than they
were in group I (Table 2).Thoracic lymph node metastasis
A total of 176 patients (28.6 %) underwent thoracic lymph
node dissection, with a median of five nodes dissected
(range 1–38). Among these, 24 patients (24/176, 13.6 %)
had lymph node metastases. There was no significant dif-
ference in the prevalence of thoracic lymph node metasta-
sis between the three groups (Table 2).Overall and recurrence-free survival based on the number
of lung metastases
The overall 5-year survival rate from pulmonary metas-
tasectomy was 64.2 %. The recurrence-free survival rate
was 34.8 % at 5 years. The CRC recurred after the treat-
ment in 279 patients (45.4 %). The 5-year overall sur-
vival rates were 70.0, 56.2, and 33.7 % in groups I, II,
and III, respectively (Fig. 2). There was a statistically sig-
nificant difference in overall survival between the three
groups (group I vs. II, p < 0.001; group II vs. III, p = 0.012).
The 5-year recurrence-free rates were 39.5, 30.6, and
8.5 % in groups I, II, and III, respectively (Fig. 3). There
was a statistically significant difference in recurrence-free
survival between the three groups in terms of the number
of pulmonary metastases (group I vs. II, p < 0.001; group
II vs. III, p = 0.056) (Fig. 4).
Fig. 1 The difference between the number of lungs resected and the number of metastases
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vival and recurrence after pulmonary metastasectomy
are summarized in Tables 3 and 4, respectively. Multi-
variate analysis revealed that age (>70 years), multipli-
city, thoracic lymph node involvement, and adjuvant
chemotherapy are all independent prognostic factors of
survival after pulmonary metastasectomy. Multiplicity
and disease-free interval are independent prognostic
factors that affect disease recurrence after pulmonary
metastasectomy.
Unilateral and bilateral metastases in patients with multiple
lesions
Among those with multiple pulmonary nodules (n = 201),
90 patients had bilateral pulmonary metastases (Fig. 2).
Eighty-six of these 90 patients (95.6 %) underwent a one-
stage surgery including sternotomy, bilateral VATS, or
thoracotomy (Table 5). The other four patients (4.4 %)
had two-stage operations (Table 5). In patients with mul-
tiple metastases, there were no significant differences in
overall survival (log rank; p = 0.666) and recurrence-free
survival (log rank; p = 0.330) between unilateral and bilat-
eral lesions.
Discussion
Many prior studies have suggested that the number of pul-
monary metastases is an important prognostic factor of sur-
vival and recurrence after pulmonary metastasectomy fromCRC [7–14]. The current surgical strategy regarding pul-
monary metastasectomy is to resect every pulmonary me-
tastases, regardless if a patient has one or multiple lesions
[15, 16]. Previously, there had been no defined cutoff num-
ber of lung metastases that would prevent possible treat-
ment by metastasectomy. Only a few reports had showed
that patients with many pulmonary nodules have a poor
prognosis after pulmonary metastasectomy. Onaitis et al.
showed that having more than three pulmonary metastases
(from CRC) was an independent poor prognostic factor of
survival after pulmonary metastasectomy [17]. Similarly,
Blackmon et al. found more than three metastases pre-
dicted poor prognosis for survival and recurrence after
metastasectomy [18]. Our data reveal that the most potent
predictor of survival and recurrence is the number of me-
tastases. Patients with a single metastasis have over fourfold
better survival than do those patients with four or more
metastases. Patients who had four or more pulmonary me-
tastases were more than twice as likely to experience a re-
currence than those patients with a single metastasis. The
5-year recurrence-free survival rate in patients with 4+ pul-
monary metastases was only 8.5 %. Therefore, patients with
four or more pulmonary metastases might not benefit from
pulmonary metastasectomy. A meticulous selection process
and multidisciplinary approach is indicated to decide treat-
ment modalities for such patients. However, it is still un-
certain whether other treatment modalities such as
chemotherapy or radiotherapy are superior to surgery
Table 2 Surgical management and pathologic findings by the number of pulmonary metastases
Characteristics The number of pulmonary metastases p valuea
All patients Group I Group II Group III
N = 615 N = 414 N = 159 N = 42
No. of lungs resectedb, mean ± sd 1.92 ± 1.77 1.17 ± 0.46 2.64 ± 1.08 6.52 ± 3.31 <0.001
No. of lung metastasesc, mean ± sd 1.66 ± 1.44 1.0 2.28 ± 0.45 5.79 ± 2.62 <0.001
Difference between no. of lungs
resected and no. of metastasesd, mean ± sd
0.25 ± 0.70 0.17 ± 0.46 0.33 ± 0.83 0.74 ± 145 <0.001
Maximum tumor size, mean ± sd 1.68 ± 1.23 1.64 ± 1.20 1.80 ± 1.34 1.67 ± 0.95 0.253
Bilaterality, n (%) 90 (14.6) 0 63 (39.6) 27 (64.3) <0.001
Lymph node metastasis, n (%)e 0.614
No lymph node dissection 439 (71.4) 303 (73.2) 108 (67.9) 28 (66.7)
Lymph node dissection 176 (28.6) 111 (26.8) 51 (32.1) 14 (33.3)
LN (−) 152 (24.7) 95 44 13
LN (+) 24 (3.9) 16 7 1
Extent of resection, n (%) 0.442
Precision excision 20 (3.3) 17 3 0
Wedge resection 439 (71.4) 300 111 28
Segmentectomy 41 (6.7) 24 15 2
Lobectomy 109 (17.7) 71 26 12
Bilobectomy/pneumonectomy 6 (0.9) 2 4 0
Surgical approach <0.001
Thoracotomy/sternotomy 244 (39.7) 118 (28.5) 93 (58.5) 33 (78.6)
VATS 371 (60.3) 296 (71.5) 66 (41.5) 9 (21.4)
aCorrelation between factors was assessed using χ2 test and Student’s t test for continuous variables
bNo. of lungs resected was defined as the number of pulmonary nodules resected in the operating room, not the number of pathologically confirmed
metastatic lesions
cNo. of lung metastases was defined as the number of pulmonary nodules that were pathologically confirmed to be metastatic cancer from CRC
dDifference between no. of lungs resected and no. of lung metastases = (no. of lung resected) − (no. of lung metastases)
eDefinitions: LN (+), thoracic lymph node dissection was performed, and at least one lymph node was positive for malignant cells; LN (−), thoracic lymph node
dissection was performed, and at least one lymph node was negative for malignant cells; no lymph node dissection, thoracic lymph node dissection was
not performed
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Therefore, it is important to emphasize that having
multiple (4+) pulmonary metastases does not rule out
the possibility of using pulmonary metastasectomy in
a patient’s treatment. Surgery may still be considered
if the patient is young, has good performance status,
has adequate pulmonary function, has no severe co-
morbidities, and has no evident of thoracic lymph
node metastasis on chest CT or PET-CT. In our study,
even patients with multiple (4+) pulmonary metastases
had >30 % 5-year overall survival rate after pulmonary
metastasectomy. It is well known that the median sur-
vival for stage IV CRC is only 5–6 months, if left un-
treated [19].
It is important to recognize that patients thought to
have solitary lesions may have also had occult microme-
tastases that were undetected, resulting in incomplete
resection. Cerfolio et al. [20] found that during metasta-
sectomy, non-imaged malignant pulmonary metastases
are found in 18 % of patients who have had a previouslytreated solid organ cancer and at least one imaged meta-
static pulmonary lesion. Therefore, a solitary lung me-
tastasis may actually be one of the several unidentified
lesions. On the other hand, pulmonary nodules that are
recognized as metastases by CT scanning are not always
true metastatic disease. Inflammatory lesions or intra-
pulmonary lymph nodes can be mistaken for cancer in
the lung. In 109 patients (17.7 %), non-metastatic lesions
were resected during surgery, in addition to truly meta-
static nodules. Although this involves removing some
normal tissue, we believe that it is safer to remove all
suspicious pulmonary nodules than it is to risk missing
lesions that are actually malignant.
Besides multiplicity, we also found that patients with a
shorter DFI (<36 months) had high rates of recurrence
after surgery. Patients with DFI <36 months had a 1.51-
fold increased risk of recurrence compared to those with
longer DFI. However, multivariate analysis did not iden-
tify DFI as an independent prognostic factor of survival
after pulmonary metastasectomy.
Fig. 2 The number of patients according to the number of pathologically confirmed pulmonary metastases after pulmonary metastasectomy
Cho et al. World Journal of Surgical Oncology  (2015) 13:222 Page 6 of 8A multidisciplinary approach is indicated when pul-
monary metastasectomy is being considered in cases
with multiple lesions. In the case of a single metastasis,
the surgical approach is aggressive as long as resectabil-
ity is confirmed. However, in patients with multiple nod-
ules, the risk of surgical comorbidities may be higher than
it is in patients with a single metastasis. Interestingly, our
data did not show a significant survival difference betweenFig. 3 Overall survival from pulmonary metastasectomy according to
the number of metastatic pulmonary nodules (group 1: single,
group 2: 2–3 nodules, group 3: 4+ nodules)patients with unilateral and bilateral lesions. In the present
study, there was no significant difference in outcome be-
tween patients with bilateral metastases compared to
those with multiple unilateral lesions. There are conflict-
ing data regarding whether the distribution of metastases
affects patient survival after pulmonary metastasectomy
[9, 21, 22]. Bilaterality is not an absolute contraindica-
tion to metastasectomy as long as the lesions can beFig. 4 Recurrence-free survival from pulmonary metastasectomy
according to the number of metastatic pulmonary nodules (group 1:
single, group 2: 2–3 nodules, group 3: 4+ nodules)
Table 5 Surgical approach in patients with bilateral pulmonary
metastases
Surgical approach No. of patients Group 2 Group 3
One-stage 86 59 27
Sternotomy 13 9 4
Bilateral VATS 29 23 6
Bilateral thoracotomy 44 27 17
Two-stage 4 4 0
Bilateral VATS 2 2
Bilateral thoracotomy 2 2
Total 90 63 27
Group 2: 2–3 pulmonary metastases; group 3: 4+ pulmonary metastases
Table 3 Multivariate analysis of factors associated with overall







>70 vs. ≤70 1.95 1.22 ~ 3.02 0.007
Surgical approach
Open surgery vs. VATS 1.39 0.97–1.99 0.070
Lymph node dissection
LN (+) vs. no
dissection
2.41 1.23–4.31 0.012
LN (+) vs. LN (−) 2.19 1.08–4.12 0.030




4+ vs. single 4.42 2.50–7.49 <0.001
4+ vs. 2–3 2.25 1.31–3.75 0.003
2–3 vs. single 1.96 1.28–2.96 0.002
Adjuvant chemotherapy
No vs. yes 1.77 1.25–2.47 0.002
Variables with a p value <0.10 were included in the multivariate analysis. Age
is a continuous variable that was represented in groups for the Kaplan–Meier
analysis. Definitions: LN (+), thoracic lymph node dissection was performed,
and at least one lymph node was positive for malignant cells; LN (−), thoracic
lymph node dissection was performed, and at least one lymph node was
negative for malignant cells; no lymph node dissection, thoracic lymph node
dissection was not performed. The Cox regression model was applied to
identify risk factors for mortality and recurrence estimating the corresponding
hazard ratios
Table 4 Multivariate analysis of the factors associated with








≤36 vs. >36 1.51 1.14 ~ 2.04 0.004
Surgical approach
Open surgery vs. VATS 1.22 0.95 ~ 1.57 0.115
Multiplicity
4+ vs. single 2.17 1.29 ~ 3.52 0.004
4+ vs. 2–3 1.43 0.90 ~ 2.22 0.123
2–3 vs. single 1.51 1.10 ~ 2.05 0.012
Bilaterality
Yes vs. no 1.00 0.67 ~ 1.49 0.990
Variables with p values <0.10 were included in the multivariate analysis.
Disease-free interval is a continuous variable that was represented in groups
for the Kaplan–Meier analysis. The Cox regression model was applied to identify
risk factors for mortality and recurrence estimating the corresponding
hazard ratios
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portant in cases of bilateral pulmonary metastases or
involvement of multiple unilateral lobes. Although we
did not address the issue of repeated metastasectomy, it
likely carries a higher risk of morbidity than does a sin-
gle procedure. Therefore, patients requiring repeated
metastasectomy should be chosen carefully after me-
ticulous evaluation.
A few prior reports have suggested that mediastinal
lymph node involvement is a prognostic factor of pul-
monary metastasectomy success. Thoracic lymph node
metastasis, which occurs in 12–19.2 % of patients with
CRC, is recognized as a poor prognostic factor [23–25].
In this study, 13.6 % (24/176) of patients had thoracic
lymph node metastases. The Cox proportional hazards
method revealed that thoracic lymph node metastasis
was a significant factor of overall survival. This finding is
consistent to that of Hamaji et al. [26], who also found
that thoracic lymph node metastasis is a negative prog-
nostic factor. However, as the group noted, it is un-
known whether thoracic or mediastinal lymph node
dissection has any therapeutic effect. Systematic lymph
node dissection is currently offered routinely for prog-
nostic purposes, but not yet for therapeutic ones.
This study has several limitations. Patients were enrolled
from a single institution, and the data were retrospectively
reviewed. Furthermore, follow-up was not completed in all
patients, and in most patients, the recurrence rates after
pulmonary metastasectomy were defined based on radio-
logic findings. Despite these limitations, our data suggest
that the surgical strategy for pulmonary metastasectomy
should be tailored to the patient depending on the number
of pulmonary metastases.
Conclusions
The overall survival and recurrence after pulmonary
metastasectomy for CRC is dependent on the number of
metastases. Surgical treatment can be offered to patients
with three or fewer pulmonary metastases. However, more
Cho et al. World Journal of Surgical Oncology  (2015) 13:222 Page 8 of 8meticulous patient selection is required to decide whether
a surgical approach is feasible in patients with four or
more pulmonary metastases.
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